Bruce Haffty, MD, and Mutlay Sayan, MD, on building radiation oncology at Rutgers, the future of the field, and a remarkable journey from eastern Turkey to Harvard faculty.
|Poll|April 16, 2012
A 67-Year-Old Male Cancer Patient Presents With a Painful Erythema Involving the Face, Arms, and Chest
Author(s)Ted Rosen, MD
Advertisement
A 67-year-old Caucasian male presents in the month of April with a spontaneously painful and tender-to-the-touch erythema involving the face, dorsal and distal forearms, dorsal hands, and V-area of the neck/anterior chest. He has cancer and is being treated with one or more chemotherapeutic agents.
Among the choices given, the patient most likely receives which drug?
Advertisement
Related to this article
Marcio A. Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with intensity-modulated proton therapy.
The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.
Community physicians must be “smart” when it comes to initiating outpatient care with agents like ramantamig for multiple myeloma, according to Jeffrey V. Matous, MD.
In the phase 3 Alliance A071801 trial, postoperative fractionated SRS improved surgical bed control vs single-fraction SRS without added toxicity.
In the phase 3 evERA trial, interim overall survival data showed a positive trend in favor of giredestrant/everolimus vs endocrine therapy plus everolimus.
William A. Hall, MD, reviews resection rates, surgical complications, and SBRT target volumes from the SOFT Preop study in pancreatic cancer.
Andy Liao, MD, discusses the distribution of KRAS mutations in biliary tract cancer and the different classes of KRAS inhibitors in development.
Advertisement
Advertisement
Trending on CancerNetwork
1
Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer
2
FDA OKs Pirtobrutinib in Frontline CLL/SLL
3
FDA Discussion Prompts Voluntary Withdrawal of BLA for I-DXd in ES-SCLC
4
Where Does Intensity-Modulated Proton Therapy Fit in Prostate Cancer?
5